TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02736838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tcpO2
Description: Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler
Study: NCT02418650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 300 mg tablet
Study: NCT02814357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: barley
Study: NCT02307344

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nigella Sativa
Study: NCT02788513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04248517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: Participants will download the app onto their smartphone and complete ecological momentary assessements
Study: NCT02295813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FBF001
Study: NCT02307344

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules that contain a placebo but look like the Nigella Sativa capsules
Study: NCT00184249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation
Description: Ablation using CE marked bipolar ablation devices
Study: NCT04336592

Intervention type: BEHAVIORAL
Intervention: Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)
Description: Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.

Intervention type: BEHAVIORAL
Intervention: Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)
Description: Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
Study: NCT02295813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01920984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of 1.25 mg of bevacizumab
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
Study: NCT02870036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan
Study: NCT02046265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Up to Prevention
Description: Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Up to Prevention: knowledge
Description: Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Up to Prevention:belief
Description: Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Offered HPV vaccine only
Description: Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
Study: NCT01467908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated transcranial magnetic brain stimulation
Description: Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
Study: NCT03488472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
Study: NCT03972592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 0.1% Sirolimus
Description: The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle
Description: The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
Study: NCT02870036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan
Study: NCT02418650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous14C-ODM-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg 14C-ODM-201 oral solution
Study: NCT01332370

Intervention type: DRUG
Intervention: Rosiglitazone + Metformin
Description: At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG

Intervention type: DRUG
Intervention: Sitagliptin + Metformin
Description: At least 180 days of continuous therapy with STG+MET after the first Rx for STG
Study: NCT02964975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Recanalisation of chronic total occlusion of coronary artery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Medical threatment according to guidelines
Study: NCT00183677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10 to 30 mg per day for 12 weeks
Study: NCT02515682

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High equol group
Description: Participants will be give natural S-equol 20mg/d for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low equol group
Description: Participants will be give natural S-equol 10mg/d for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be give placebo for 24 weeks.
Study: NCT00810550

Intervention type: OTHER
Group type: OTHER
Intervention: Carotid ultrasound
Description: Measurement of intima-media thickness
Study: NCT02817217

Intervention type: DRUG
Group type: OTHER
Intervention: SP2086
Description: SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
Study: NCT02174562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care-Occupational Therapy
Description: PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care
Description: Usual care enhanced with education and attention
Study: NCT00545376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment - in clinic
Description: I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment - at home
Description: One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
Study: NCT02870036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and Leucovorin Calcium
Study: NCT00545376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education to physicians
Description: I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
Study: NCT02490176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide were taken daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo were taken daily for 7 days
Study: NCT03419156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Arm Intervention
Description: Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
Study: NCT02870036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and Leucovorin Calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study: NCT00208078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure support ventilator
Description: Non invasive ventilation 4h/d 5 days a week
Study: NCT02775981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX0041-002
Study: NCT00586014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Dose Sequential Chemotherapy followed by ASCT
Description: Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
Study: NCT00565708

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Adjuvant Therapy
Study: NCT04045743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABp1 (Bermekimab) OR Placebo
Description: Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABp1 (Bermekimab) OR Placebo
Description: Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABp1 (Bermekimab)
Description: Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABp1 (Bermekimab)
Description: Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
Study: NCT02117843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVI® Arsenic trioxide drug eluting stent
Description: AVI® Arsenic trioxide drug eluting stent
Study: NCT01806714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text-based reminder for recommended HPV vaccine or WCC
Description: Patients due for a well visit or HPV vaccine received a text reminder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-specific text-based reminder (general health tip)
Description: Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
Study: NCT01190150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
Study: NCT00866762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor (MK-0683)
Description: 400 mg once daily for 6 months
Study: NCT03096184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: 500 mg qd.p.o. every day for 21 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur Gimeracil Oteracil Potassium Capsules
Description: 50mg bid p.o. every day for 14 days as a cycle
Study: NCT01805414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Carbohydrate Breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Breakfast
Study: NCT03408860

Intervention type: OTHER
Group type: OTHER
Intervention: Countering Emotional Behaviors Module from Unified Protocol
Description: This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.

Intervention type: OTHER
Group type: OTHER
Intervention: Countering Emotional Behaviors Module from Unified Protocol
Description: This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
Study: NCT02580812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical and neuropsychological evaluation procedure
Description: WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and neuropsychological evaluation procedure
Description: WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
Study: NCT03736005

Intervention type: OTHER
Intervention: Exposure of significant critical illness
Description: Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.

Intervention type: OTHER
Intervention: Exposure of significant critical illness
Description: Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
Study: NCT02181348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: dl-alpha tocopheryl acetate 400 mg once daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (edible oil)
Study: NCT01014858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
Study: NCT01879371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen+caffeine FDC
Description: oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (Nurofen Immedia®)
Description: oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (Brufen®)
Description: oral dose
Study: NCT02167243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for BG testing
Description: Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Subjects receive standard of care
Study: NCT00578617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Metoprolol 50-100mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Atenolol 50-100mg,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Propranolol 40-80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Acebutolol 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Carvedilol 6.25mg
Study: NCT02661607

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Point of care echocardiography
Description: Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography

Intervention type: DEVICE
Group type: OTHER
Intervention: Central venous catheter placement
Description: Central venous catheter placement is performed as per local guidelines in critically ill patients

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest radiography
Description: Routine chest radiography is performed after central venous catheter placement in critically ill patients
Study: NCT05275153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based cognitive rehabilitation program
Description: The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
Study: NCT00532883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Pidolate
Description: HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Pidolate
Description: HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pills and Placebo Liquid
Description: HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
Study: NCT04090281

Intervention type: GENETIC
Group type: OTHER
Intervention: CYP2C19 genotyping
Description: Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
Study: NCT04664920

Intervention type: DEVICE
Intervention: exergame
Description: motor-cognitive training device
Study: NCT02642887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mTA + SCTG
Description: These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
Study: NCT04077242

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic Fallopian tube assessment using the Parryscope technique
Description: A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic Fallopian tube assessment using the Tubal flow technique
Description: a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia.